Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib maintenance after TACE for advanced hepatocellular carcinoma
ChiCTR1800017503Phase 4Not yet recruiting
- Sponsor
- Army Specialized Medical Center
- Start
- Aug 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Army Specialized Medical Center. Primary endpoint: Progression-free survival. Planned start Aug 2018; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1800017503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017503.